Rosetta Genomics Ltd. (NASDAQ:ROSG) has traded as high as $23.43 for a possible gain of 1346% during today’s trading session and last traded at $19 for a gain of 69.04% from yesterday’s close and 1072.83% from my 5.15 alert at $1.62!! ROSG shares have traded as high as $36.43 over the past 52 weeks, which is 35.68% off that high at last traded stock price. Get my next ALERT 100% FREE
In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of competing companies, the ones with quality drugs and proven technologies stand to gain the most.
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a “first to invent” to a “first to file” system. The majority of countries around the world have already adopted the “first to file” system. The AIA will help benefit biotech companies “by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system.” BIO President and CEO Jim Greenwood stated in a press release: “Small biotechnology companies rely heavily on their patents to attract investment,” and “they will benefit from the improvements to our nation’s patent system made by this legislation,” added Greenwood.
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, earlier this week announced that Novitas, the designated Medicare Administrative Contractor for the Company’s miRview® mets2 assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview® mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient.
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
- See today’s top stock picks and market analysis
- Want more? Check out the message board buzz for these stocks
- See what newsletters are recommending these stock picks
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
- This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.